The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
|Articles|November 7, 2012
FDA approves agent for RA patients who do not respond to methotrexate
FDA has approved tofacitinib (Xeljanz, Pfizer) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.
Advertisement
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
3
New Report Finds Pharmacies Key in Long-Term GLP-1 Success
4
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
5